Evidence map›Paper›PMID 38310502›Full record

ArticleMayo Clinic proceedings2024

Clinicopathologic Characteristics, Etiologies, and Outcome of Secondary Oxalate Nephropathy.

Samih H Nasr, Anthony M Valeri, Samar M Said, Sanjeev Sethi, Karl A Nath, John C Lieske, Lihong Bu

Open access · greenAbstract read
In one paragraph

Article in Mayo Clinic proceedings, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Diet-induced hyperoxaluria: A case based mini-review.Clinical nephrology. Case studies · 2024
    Article
  7. Delayed Graft Function After Kidney Transplantation: The Role of Residual Diuresis and Waste Products, as Oxalic Acid and Its Precursors.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Samih H NasrDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. Electronic address: nasr.samih@mayo.edu.
Anthony M ValeriDivision of Nephrology, Columbia University College of Physicians and Surgeons, New York, NY.
Samar M SaidDepartment of Pathology, Olmsted Medical Center, Rochester, MN.
Sanjeev SethiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Karl A NathDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
John C LieskeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Lihong BuDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · USColumbia University · USMayo Clinic · USOlmsted Medical Center · US

Funding

An individualized medicine approach to urinary stone diseaseR01DK133171 · NIDDK · MAYO CLINIC ROCHESTER · PI Peter C. Harris, Felix Knauf · 2022 to 2026
$3.0M
NIDDK NIH HHS R01 DK133171
6 · The paper itself

Abstract

objectiveTo report the clinicopathologic characteristics, prognostic indicators, prognosis, and transplant outcome of secondary oxalate nephropathy (ON). PATIENTS AND

methodsWe performed a retrospective analysis of 113 consecutive patients with secondary ON diagnosed at Mayo Clinic in Rochester, Minnesota, between January 1, 2001, and March 1, 2023.

resultsThe incidence of secondary ON among all native biopsies from Mayo Clinic patients over the study period (n=11,617) was 0.97%. ON was attributed to enteric hyperoxaluria in 60% of the 113 patients (68; most commonly Roux-en-Y gastric bypass), excessive ingestion of foods high in oxalate or oxalate precursors in 23% (26) (most commonly vitamin C), and idiopathic in 17% (19). Most patients presented with acute kidney injury (AKI) (particularly in the ingestion group) or AKI on chronic kidney disease, and 53% (60 of 113) were diabetic. Calcium oxalate crystals were accompanied by acute tubular injury, inflammation, and interstitial fibrosis and tubular atrophy. Concurrent pathologic conditions were present in 53% of the patients (60 of 113), most commonly diabetic nephropathy. After a median follow-up of 36 months, 27% of the patients (30 of 112) had kidney recovery, 19% (21 of 112) had persistent kidney dysfunction, 54% (61 of 112) had development of kidney failure, and 29% (32 of 112) died. The mean kidney survival was worse for patients with a concurrent pathologic lesion (30 months vs 96 months for those without a concurrent pathologic lesion; P<.001). Independent predictors of kidney failure were the degree of interstitial fibrosis and tubular atrophy and nadir estimated glomerular filtration rate but not the degree of crystal deposition. After a median follow-up of 58 months in 23 patients who received kidney transplant, 4 had graft loss (due to ON in 3). The 2-, 5-, and 10-year graft survivals were 90% (18 of 20), 79% (11 of 14), and 50% (6 of 12).

conclusionON is a rare cause of AKI or AKI on chronic kidney disease. Most patients have comorbid pathologic conditions, particularly diabetic nephropathy, which worsen the prognosis. Recurrence in the renal allograft and graft loss may occur if hyperoxaluria is not controlled.

Indexed as

Acute Kidney InjuryDiabetic NephropathiesHyperoxaluriaKidney TransplantationRenal Insufficiency, ChronicAtrophyFibrosisHumansOxalatesRetrospective StudiesOxalates

Identifiers

PMID38310502
PMCPMC11017309
OpenAlexW4391481859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.